expected to reach USD 5.63 billion by 2028 registering a
CAGR of 11.3% over the forecast period, according to a new report by Grand View Research, Inc. Use of drug discovery software for gaining market intelligence owing to several advantages, such as rapid drug design & synthesis, efficient tracking of disease evolution, and data integrity management, has increased significantly among the researchers in the recent years, driving the industry growth.
Key suggestions from the report:
The discovery workflow segment accounted for the largest share of 59.19% in 2020 owing to the increased focus of pharmaceutical companies on the development of novel drug candidates
The development workflow segment is expected to register the fastest CAGR from 2021 to 2028 owing to a rise in the number of drug candidates in the clinical development phase